CARA (NASDAQ) stock page - price, fundamentals, dividends - iOCharts

CARA

12.61
-0.35 (-2.70%)
Cara Therapeutics, Inc (NASDAQ, USD)
Healthcare >
Biotechnology
Market cap
631.16M
Ent value
628.41M
Price/Sales
4.67
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
75.05
Forward P/E
-
PEG
-
EPS growth
-24.10%
1 year return
-28.56%
3 year return
-12.86%
5 year return
20.23%
10 year return
-
Last updated: 2021-07-23

STOCK INFORMATION

Stock chart
Loading...
Stock price data
All-time high29.19
1y analyst estimate27.63
Beta1.13
EPS (TTM)0.17
Dividend per share-
Ex-div date-
Next earnings date9 Aug 2021
Downside potential
Loading...
Downside potential data
CARAS&P500
Current price drop from All-time high-56.80%-0.37%
Highest price drop-80.50%-56.47%
Date of highest drop27 Jun 20169 Mar 2009
Avg drop from high-42.13%-11.54%
Avg time to new high99 days13 days
Max time to new high948 days1805 days

DIVIDENDS

CARA does not pay dividends

FINANCIALS

Per share
Loading...
Per share data
Current share count50.05M
EPS (TTM)0.17
FCF per share (TTM)-0.12
Income statement
Loading...
Income statement data
Revenue (TTM)135.08M
Gross profit (TTM)135.08M
Operating income (TTM)5.38M
Net income (TTM)8.41M
EPS (TTM)0.17
EPS (1y forward)-0.80
Margins
Loading...
Margins data
Gross margin (TTM)100.00%
Operating margin (TTM)3.99%
Profit margin (TTM)6.23%
Balance Sheet
Loading...

Please create a free account or log in to access this chart

Balance Sheet data
Cash22.52M
Net receivables3.75M
Total current assets188.35M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment4.74M
Total assets250.23M
Accounts payable14.88M
Short/Current long term debt4.89M
Total current liabilities16.52M
Total liabilities19.77M
Shareholder's equity0.00
Net tangible assets233.71M
Cash flow
Loading...

Please create a free account or log in to access this chart

Cash flow data
Operating cash flow (TTM)-5.49M
Capital expenditures (TTM)713.00K
Free cash flow (TTM)-6.20M
Dividends paid (TTM)0.00
Financial returns
Loading...

Please create a free account or log in to access this chart

Financial returns data
Return on Equity3.38%
Return on Assets3.10%
Return on Invested Capital3.38%
Cash Return on Invested Capital-2.49%
COMPANY DETAILS
CARA (Cara Therapeutics, Inc) company logo
Marketcap
631.16M
Marketcap category
Small-cap
Description
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Employees
80
SEC filings
CEO
Derek Chalmers
Country
USA
City
Stamford
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Loading...